The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Abnormalities in Glucose Regulation During Antipsychotic Treatment of Schizophrenia
Abstract
BACKGROUND: Hyperglycemia and type 2 diabetes mellitus are more common in schizophrenia than in the general population. Glucoregulatory abnormalities have also been associated with the use of antipsychotic medications themselves. While antipsychotics may increase adiposity, which can decrease insulin sensitivity, disease- and medication-related differences in glucose regulation might also occur independent of differences in adiposity. METHODS: Modified oral glucose tolerance tests were performed in schizophrenic patients (n = 48) receiving clozapine, olanzapine, risperidone, or typical antipsychotics, and untreated healthy control subjects (n = 31), excluding subjects with diabetes and matching groups for adiposity and age. Plasma was sampled at 0 (fasting), 15, 45, and 75 minutes after glucose load. RESULTS: Significant time x treatment group interactions were detected for plasma glucose (F(12,222) = 4.89, P<.001) and insulin (F(12,171) = 2.10, P =.02) levels, with significant effects of treatment group on plasma glucose level at all time points. Olanzapine-treated patients had significant (1.0-1.5 SDs) glucose elevations at all time points, in comparison with patients receiving typical antipsychotics as well as untreated healthy control subjects. Clozapine-treated patients had significant (1.0-1.5 SDs) glucose elevations at fasting and 75 minutes after load, again in comparison with patients receiving typical antipsychotics and untreated control subjects. Risperidone-treated patients had elevations in fasting and postload glucose levels, but only in comparison with untreated healthy control subjects. No differences in mean plasma glucose level were detected when comparing risperidone-treated vs typical antipsychotic-treated patients and when comparing typical antipsychotic-treated patients vs untreated control subjects. CONCLUSION: Antipsychotic treatment of nondiabetic patients with schizophrenia can be associated with adverse effects on glucose regulation, which can vary in severity independent of adiposity and potentially increase long-term cardiovascular risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
The hormone resistin links obesity to diabetes
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., & Lazar, M. A. (2001) · Nature · doi:10.1038/35053000 · Cited by 4,755
Harris, M. I., Flegal, K. M., Cowie, C. C., Eberhardt, M. S., Goldstein, D. E., Little, R. R., Wiedmeyer, H.-M., & Byrd-Holt, D. D. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.518 · Cited by 2,703
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Diagnostic Interview for Genetic Studies: Rationale, Unique Features, and Training
Nurnberger, J. I. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950110009002 · Cited by 2,053
Coutinho, M., Gerstein, H. C., Wang, Y., & Yusuf, S. (1999) · Diabetes Care · doi:10.2337/diacare.22.2.233 · Cited by 1,685
Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised
Kobylski, T. P. (1988) · Psychosomatics · doi:10.1016/s0033-3182(88)72438-x · Cited by 1,054
Diabetes Mellitus: Report of a WHO Study Group.
(1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-104-4-597_2 · Cited by 1,022
The homeostasis model in the San Antonio Heart Study.
Haffner, S. M., Miettinen, H., & Stern, M. P. (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1087 · Cited by 788
CORONARY-HEART-DISEASE RISK AND IMPAIRED GLUCOSE TOLERANCE The Whitehall Study
Fuller, J., Shipley, M., Rose, G., Jarrett, R. J., & Keen, H. (1980) · The Lancet · doi:10.1016/s0140-6736(80)92651-3 · Cited by 783
Clozapine, Diabetes Mellitus, Weight Gain, and Lipid Abnormalities: A Five-Year Naturalistic Study
Henderson, D. C., Cagliero, E., Gray, C., Nasrallah, R. A., Hayden, D. L., Schoenfeld, D. A., & Goff, D. C. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.6.975 · Cited by 701
Fuller, J. H., Shipley, M. J., Rose, G., Jarrett, R. J., & Keen, H. (1983) · BMJ · doi:10.1136/bmj.287.6396.867 · Cited by 633
Effects of weight loss on regional fat distribution and insulin sensitivity in obesity.
Goodpaster, B. H., Kelley, D. E., Wing, R. R., Meier, A., & Thaete, F. L. (1999) · Diabetes · doi:10.2337/diabetes.48.4.839 · Cited by 608
Determination of Free and Total Insulin and C-Peptide in Insulin-treated Diabetics
Kuzuya, H., Blix, P. M., Horwitz, D. L., Steiner, D. F., & Rubenstein, A. H. (1977) · Diabetes · doi:10.2337/diab.26.1.22 · Cited by 603
Antipsychotic-induced weight gain: a review of the literature.
Allison, D. B., & Casey, D. E. (2001) · PubMed · Cited by 595
Novel antipsychotics and new onset diabetes
Wirshing, D. A., Spellberg, B. J., Erhart, S. M., Marder, S. R., & Wirshing, W. C. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00100-0 · Cited by 407
Lustman, P. J., Griffith, L. S., Clouse, R. E., Freedland, K. E., Eisen, S. A., Rubin, E. H., Carney, R. M., & McGill, J. B. (1997) · Psychosomatic Medicine · doi:10.1097/00006842-199705000-00007 · Cited by 405
Diabetes mellitus in schizophrenic patients
Mukherjee, S., Decina, P., Bocola, V., Saraceni, F., & Scapicchio, P. (1996) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(96)90054-1 · Cited by 368
Body weight gain induced by antipsychotic drugs: mechanisms and management
Baptista, T. (1999) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1999.tb10908.x · Cited by 304
Hyperglycemic Crises in Urban Blacks
Umpierrez, G. E. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.157.6.669 · Cited by 295
Clozapine-induced weight gain: prevalence and clinical relevance
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.1.68 · Cited by 248
Drug-Induced Disorders of Glucose Tolerance
Pandit, M. K., Burke, J., Gustafson, A. B., Minocha, A., & Peiris, A. N. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-7-199304010-00008 · Cited by 239
Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate
Fontaine, K. R., Heo, M., Harrigan, E. P., Shear, C. L., Lakshminarayanan, M., Casey, D. E., & Allison, D. B. (2001) · Psychiatry Research · doi:10.1016/s0165-1781(01)00234-7 · Cited by 230
FAMILY HISTORY OF TYPE 2 DIABETES IN SCHIZOPHRENIC PATIENTS
Mukherjee, S., Schnur, D., & Reddy, R. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91392-5 · Cited by 224
Long-Term Glycemic Control Relates to Mortality in Type II Diabetes
Andersson, D. K., & Svärdsudd, K. (1995) · Diabetes Care · doi:10.2337/diacare.18.12.1534 · Cited by 221
Body Weight and Leptin Plasma Levels During Treatment With Antipsychotic Drugs
Kraus, T., Haack, M., Schuld, A., Hinze-Selch, D., K�hn, M., Uhr, M., & Pollm�cher, T. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.2.312 · Cited by 221
New-Onset Diabetes Mellitus and Diabetic Ketoacidosis Associated With Olanzapine Treatment
Goldstein, L. E., Sporn, J., Brown, S., Kim, H., Finkelstein, J., Gaffey, G. K., Sachs, G., & Stern, T. A. (1999) · Psychosomatics · doi:10.1016/s0033-3182(99)71210-7 · Cited by 220
Hagg, S., Joelsson, L., Mjorndal, T., Spigset, O., Oja, G., & Dahlqvist, R. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0604 · Cited by 211
Davidson, M. B., Schriger, D. L., Peters, A. L., & Lorber, B. (1999) · JAMA · doi:10.1001/jama.281.13.1203 · Cited by 189
The Brief Psychiatric Rating Scale in Psychopharmacology Research
Overall, J. E. (2015) · Modern Trends in Pharmacopsychiatry · doi:10.1159/000395069 · Cited by 188
Clozapine and Associated Diabetes Mellitus
Popli, A. P., Konicki, P. E., Jurjus, G. J., Fuller, M. A., & Jaskiw, G. E. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0304 · Cited by 185
FACTORS CONTRIBUTING TO DEATHS OF DIABETICS UNDER FIFTY YEARS OF AGE
Tunbridge, W. M. G. (1981) · The Lancet · doi:10.1016/s0140-6736(81)90950-8 · Cited by 183
The neurobiology of attention-deficit/hyperactivity disorder.
Zametkin, A. J., & Liotta, W. (1998) · PubMed · Cited by 176
Plasma Cortisol Determination: Radioimmunoassay and Competitive Protein Binding Compared
Farmer, R. W., & Pierce, C. E. (1974) · Clinical Chemistry · doi:10.1093/clinchem/20.4.411 · Cited by 170
Olanzapine-Induced Ketoacidosis With Diabetes Mellitus
LINDENMAYER, J., & PATEL, R. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.9.1471 · Cited by 169
The relationship of pharmacology to side effects.
Casey, D. E. (1997) · PubMed · Cited by 168
Park, S., Barrett-Connor, E., Wingard, D. L., Shan, J., & Edelstein, S. (1996) · Diabetes Care · doi:10.2337/diacare.19.5.450 · Cited by 161
Characteristics of Diabetic Ketoacidosis in Older versus Younger Adults
Malone, M. L., Gennis, V. M., & Goodwin, J. S. (1992) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1992.tb01797.x · Cited by 150
Differential effects of BMI on diabetes risk among black and white Americans.
Resnick, H. E., Valsania, P., Halter, J. B., & Lin, X. (1998) · Diabetes Care · doi:10.2337/diacare.21.11.1828 · Cited by 147
Phenothiazines and Diabetes in Hospitalized Women
Thonnard‐Neumann, E. (1968) · American Journal of Psychiatry · doi:10.1176/ajp.124.7.978 · Cited by 145
Banerji, M. A., Lebowitz, J., Chaiken, R. L., Gordon, D., Kral, J. G., & Lebovitz, H. E. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.2.e425 · Cited by 142
Bodyweight Change as an Adverse Effect of Drug Treatment: Mechanisms and Management
Pijl, H., & Meinders, A. E. (1996) · Drug Safety · doi:10.2165/00002018-199614050-00005 · Cited by 139
DELAYED ACTION OF INSULIN IN SCHIZOPHRENIA
Braceland, F. J., Meduna, L. J., & VAICHULIS, J. A. (1945) · American Journal of Psychiatry · doi:10.1176/ajp.102.1.108 · Cited by 129
Clozapine-Associated Elevation in Serum Triglycerides
Gaulin, B. D., Markowitz, J. S., Caley, C. F., Nesbitt, L. A., & Dufresne, R. L. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.8.1270 · Cited by 119
Madhusoodanan, S., Brenner, R., Araujo, L., & Abaza, A. (1995) · PubMed · Cited by 112
Hyperglycemia Associated With Olanzapine
Fertig, M. K., Brooks, V. G., Shelton, P. S., & English, C. W. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n1208c · Cited by 110
New-Onset Diabetes Mellitus Associated With the Initiation of Quetiapine Treatment
Sobel, M., Jaggers, E. D., & Franz, M. A. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0809f · Cited by 107
Olanzapine-Induced Glucose Dysregulation
Bettinger, T. L., Mendelson, S. C., Dorson, P. G., & Crismon, M. L. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.19327 · Cited by 105
Osmoregulation in clinical disorders of thirst appreciation
McKenna, K., & Thompson, C. J. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00572.x · Cited by 104
Metabolic changes during treatment with valproate in humans: Implication for untoward weight gain
Breum, L., Astrup, A. V., Gram, L. F., Andersen, T., Stokholm, K. H., Christensen, N. J., Werdelin, L., & Madsen, J. (1992) · Metabolism · doi:10.1016/0026-0495(92)90061-e · Cited by 102
Intra-abdominal fat: is it a major factor in developing diabetes and coronary artery disease?
Kissebah, A. H. (1996) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(96)80035-0 · Cited by 100
Ober, S. K., Hudak, R., & Rusterholtz, A. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.6.970 · Cited by 93
Sex Differences in Fasting Glycemia as a Risk Factor for Ischemic Heart Disease Death
Scheidt‐Nave, C., Barrett-Connor, E. L., Wingard, D. L., Cohn, B. A., & Edelstein, S. L. (1991) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115928 · Cited by 86
Serum triglyceride levels in patients treated with clozapine
Ghaeli, P., & Dufresne, R. L. (1996) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/53.17.2079 · Cited by 85
HYPERGLYCEMIA AND GLYCOSURIA FOLLOWING CHLORPROMAZINE THERAPY
Hiles, B. W. (1956) · JAMA · doi:10.1001/jama.1956.02970350067022 · Cited by 84
Diabetic Ketoacidosis Associated With Risperidone Treatment?
Croarkin, P. E., Jacobs, K. M., & Bain, B. K. (2000) · Psychosomatics · doi:10.1176/appi.psy.41.4.369 · Cited by 82
Glucose-Induced Increase in Memory Performance in Patients With Schizophrenia
Newcomer, J. W., Craft, S., Fucetola, R. P., Moldin, S. O., Selke, G., Paras, L., & Miller, R. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033381 · Cited by 81
Self-citationKetoacidosis as a side‐effect of clozapine: a case report
Kostakolu, A. E., Yazici, M. K., Erbas, T. A., & Guvener, N. D. (1996) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1996.tb10635.x · Cited by 78
Uvnäs-Moberg, K., Ahlénius, S., Alster, P., & Hillegaart, V. (2008) · Neuroendocrinology · doi:10.1159/000126970 · Cited by 74
Ensinck, J. W. (1983) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-68866-9_10 · Cited by 72
Olanzapine-Induced Elevation of Plasma Triglyceride Levels
Sheitman, B., BIRD, P. M., Binz, W., AKINLI, L., & SANCHEZ, C. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.9.1471-a · Cited by 69
CARBOHYDRATE METABOLISM IN BRAIN DISEASE
HENNEMAN, D. H. (1954) · A M A Archives of Internal Medicine · doi:10.1001/archinte.1954.00250030072008 · Cited by 68
Chaouloff, F., Laude, D., & Baudrie, V. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90370-l · Cited by 65
Is glucose a continuous risk factor for cardiovascular mortality?
Gerstein, H. C. (1999) · Diabetes Care · doi:10.2337/diacare.22.5.659 · Cited by 60
Adverse effects of the atypical antipsychotics
Meltzer, H. Y. (1998) · The Journal of Clinical Psychiatry · Cited by 60
Glucose-insulin metabolism in chronic schizophrenia.
Brambilla, F., Guastalla, A., Guerrini, A., Riggi, F., Rovere, C., Zanoboni, A., & Zanoboni-Muciaccia, W. (1976) · PubMed · Cited by 54
Evaluation of Three Potential Screening Tests for Diabetes Mellitus in a Biethnic Population
Haffner, S. M., Rosenthal, M., Hazuda, H. P., D, M. P. S. M., & Franco, L. J. (1984) · Diabetes Care · doi:10.2337/diacare.7.4.347 · Cited by 52
New-onset diabetes mellitus associated with quetiapine.
Procyshyn, R. M., Pande, S. D., & Tse, G. (2000) · PubMed · Cited by 52
Age- and dose-dependent glucose-induced increases in memory and attention in schizophrenia
Fucetola, R. P., Newcomer, J. W., Craft, S., & Melson, A. K. (1999) · Psychiatry Research · doi:10.1016/s0165-1781(99)00063-3 · Cited by 51
Self-citationPatients with schizophrenia who smoke: Private disaster, public resource
McCreadie, R. G., & Kelly, C. (2000) · The British Journal of Psychiatry · doi:10.1192/bjp.176.2.109 · Cited by 50
Clozapine-Induced Diabetic Ketoacidosis
Smith, H., Kenney‐Herbert, J., & Knowles, L. (1999) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/0004867900027 · Cited by 50
Elevated Serum Triglycerides with Clozapine Resolved with Risperidone in Four Patients
Dufresne, R. L., & Ghaeli, P. (1999) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.19.13.1099.31586 · Cited by 47
Valproate causes metabolic disturbance in normal man.
Turnbull, D. M., Dick, D. J., Wilson, L., Sherratt, H. S. A., & Alberti, K. G. M. M. (1986) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.49.4.405 · Cited by 45
Type 2 diabetes mellitus: the grand overview
Ratner, R. E. (1998) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(1998120)15:4+<s4::aid-dia735>3.0.co;2-1 · Cited by 44
Csako, G., McGriff, N. J., Rotman-Pikielny, P., Sarlis, N. J., & Pucino, F. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.1a031 · Cited by 40
Yamada, J., Sugimoto, Y., Yoshikawa, T., Kimura, I., & Horisaka, K. (1995) · Life Sciences · doi:10.1016/0024-3205(95)02010-g · Cited by 39
Glucose-insulin metabolism in chronic schizophrenia
Brambilla, F., Guastalla, A., Guerrini, A., Riggi, F., Rovere, C., Zanoboni, A., & Zanoboni-Muciaccia, W. (1975) · Progress in brain research · doi:10.1016/s0079-6123(08)63700-0 · Cited by 37
Hyperglykämie und Ketoazidose unter Olanzapin
Hayek, D. V., Hüttl, V., Reiss, J., Schweiger, H.-D., & Füeßl, H. S. (1999) · Der Nervenarzt · doi:10.1007/s001150050520 · Cited by 37
Diabetes Mellitus Associated with Clozapine Therapy
Wehring, H. J., Alexander, B., & Perry, P. J. (2000) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.9.844.35201 · Cited by 37
Lithium Carbonate-Induced Nephrogenic Diabetes Insipidus and Glucose Intolerance
Martínez–Maldonado, M. (1973) · Archives of Internal Medicine · doi:10.1001/archinte.1973.03650120081015 · Cited by 30
Temelkova-Kurktschiev, T. S., Henkel, E., Schäper, F., Koehler, C., Siegert, G., & Hanefeld, M. (2000) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2000-5802 · Cited by 25
Fluoxetine therapy in obese diabetic and glucose intolerant patients.
Kutnowski, M., Daubresse, J., Friedman, H. T., Kolanowski, J., Krzentowski, G., Scheen, A. J., & Gaal, L. V. (1992) · PubMed · Cited by 20
Haemolytic anemia, jaundice and diabetes mellitus following chlorpromazine therapy.
Aa, C., & Eidlow, S. (1956) · PubMed · Cited by 16
Sato, S., KATAYAMA, K., Kakemi, M., et al. (1988) · Journal of Pharmacobio-Dynamics · doi:10.1248/bpb1978.11.492 · Cited by 10
Intra-abdominal fat: is it a major factor in developing diabetes and coronary artery disease?
Kissebah, A. H. (1996) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(96)80053-2 · Cited by 6
Lithium carbonate-induced nephrogenic diabetes insipidus and glucose intolerance
Martinez-Maldonado, M. (1973) · Archives of Internal Medicine · doi:10.1001/archinte.132.6.881 · Cited by 3
Cited by
Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554
Second-Generation (Atypical) Antipsychotics and Metabolic Effects: A Comprehensive Literature Review
Newcomer, J. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519001-00001 · Cited by 1,340
Self-citationPhysical illness and schizophrenia: a review of the literature
Leucht, S., Burkard, T., Henderson, J., Maj, M., & Sartorius, N. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2007.01095.x · Cited by 633
Diet, smoking and cardiovascular risk in people with schizophrenia: Descriptive study
McCreadie, R. G., & Scottish Schizophrenia Lifestyle Group (2003) · British Journal of Psychiatry · doi:10.1192/03-162 · Cited by 546
Lindenmayer, J.-P., Czobor, P., Volavka, J., Citrome, L., Sheitman, B., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.290 · Cited by 465
Metadata
- Authors
- Newcomer, J. W., Haupt, D. W., Fucetola, R., Melson, A. K., Schweiger, J. A., Cooper, B. P., & Selke, G.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2002-04-01
- Volume
- 59
- Issue
- 4
- Pages
- 337
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2079567719
- Cited by
- 520
- References
- 89
- FWCI
- 32.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.